Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparative Efficacy and Safety of Fenoverine and Trimebutine Maleate in Irritable Bowel Syndrome; A Randomized Double-blind Parallel Multi-center Phase IV Trial

NCT01507922 is registered in ClinicalTrials.gov with Bukwang Pharmaceutical as lead sponsor.

NCT NCT01507922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01507922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparative Efficacy and Safety of Fenoverine and Trimebutine Maleate in Irritable Bowel Syndrome; A Randomized Double-blind Parallel Multi-center Phase IV Trial
Lead sponsor
Bukwang Pharmaceutical
Phase
Phase 4
Overall status
Completed
Start date
December 31, 2011
Completion date
June 30, 2013
Enrollment
186 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

irritable bowel syndrome